Avanir announced that Nuedexta (dextromethorphan hydrobromide and quinidine sulfate capsules) is now available for the treatment of pseudobulbar affect. Pseudobulbar affect is a neurologic condition causing involuntary, sudden and frequent episodes of laughing and crying in patients with certain underlying neurologic diseases or injuries. Pseudobulbar affect episodes typically occur out of proportion or incongruent to the patient’s underlying emotional state.
Nuedexta contains 20mg of dextromethorphan hydrobromide and 10mg of quinidine sulfate. Nuedexta acts on sigma-1 and NMDA receptors in the brain, although the mechanism by which Nuedexta exerts therapeutic effects in patients with PBA is unknown.
For more information call (855) 468-3339 or visit www.nuedexta.com.